$ICU Cashflow Statement | Understand Stock

$ICU

$2.52 +$0.05 (2.02%) Close

$ICU Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities
Amortization of discount on notes payable
Non-cash accrued interest related to convertible notes
Change in fair value of notes payable derivative liability
Change in fair value of convertible notes
Change in fair value of forward purchase agreement derivative liability
Amortization of deferred financing costs
Change in fair value of convertible notes (issued, converted and outstanding)
Change in fair value of liability classified warrants (exercised and outstanding)
Interest earned in trust account
Change in fair value of forward option
Loss on sale of recycled shares
PPP loan forgiveness
Shares issued for the standby equity purchase agreement commitment fee
Stock-based compensation
Loss on extinguishment of convertible notes

Change in operating assets and liabilities
Accounts receivables, net
Other receivables
Inventory
Prepaid expenses
Accounts payable and accrued expenses
Other assets
Accounts payable
Accrued expenses and other current liabilities
Accrued expenses
Other liabilities
Net cash used in operating activities

Investment in trust account
Net cash used in financing activities
Cash flows from financing activities
Proceeds from issuance of convertible notes
Proceeds from recapitalization
Payment of recapitalization transaction costs
Proceeds from PIPE investors
Payment for forward contracts
Proceeds from issuance of shares, net of offering costs
Proceeds from exercise of warrants
Additional warrants
Proceeds from issuance of pre-funded warrants
Proceeds from exercise of additional warrants
Payment of commitment fee - equity line of credit
Proceeds from sale of recycled shares
Proceeds from pre-funded warrants
Proceeds from notes - related party
Proceeds from issuance of IPO units, net of offering costs
Repayment from notes and advances payable - related party
Proceeds from issuance of notes payable
Proceeds from PPP loan
Payment of notes payable
Repayment of PPP loan
Net cash provided by financing activities

Net increase in cash
CASH - BEGINNING OF YEAR
CASH - END OF PERIOD
Cash, beginning of period
Cash, end of period
Net increase in cash
Cash, beginning of year
Cash, end of year
Supplemental disclosure of cash flow information
Reclassification of warrants to liability
Deferred underwriting commissions in connection with the initial public offering
Initial Classification of Class A shares subject to redemption
Representative Class A shares issued to Maxim
Class B dividend stock issued to Sponsor
Cash paid for interest

Conversion of Series A-2 Preferred stock into Series B Preferred stock
Value of derivative liability on issuance of convertible notes
Noncash conversion of accrued expenses into convertible notes
Conversion of Preferred stock to common stock
Conversion of notes payable to common stock
Recapitalization transaction costs in accounts payable
Recapitalization transaction costs in notes payable
Cash paid for income taxes
Exercise of liability classified warrants
Shares issued as payment of convertible notes
Shares issued to settle forward option-prepaid forward contracts
Board compensation settled in shares of common stock in-lieu-of-cash
Shares issued from conversion of convertible notes
Conversion of Notes into Common Stock
Total shares issued from conversion of convertible notes
Offering cost incurred but not paid
Conversion of convertible notes to common stock
Other receivables of cash in transit for convertible notes
Board compensation settled in shares of common stock in lieu of cash
Issuance of convertible note warrants

Comments